Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045955 · ClinicalTrials.gov registry record · Phase 3
Long-Term Safety Performance of Fexofenadine in Asthma
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,200
- Enrollment target
NCT00045955 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 1,200 participants.
The verdict
NCT00045955, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,200 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the long-term safety performance of fexofenadine compared to montelukast in subjects with asthma
Interventions
- DRUG Fexofenadine, Comparator = Montelukast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2002-02 |
| Est. Completion | 2003-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00045955
The ClinicalTrials.gov registry entry for NCT00045955 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fexofenadine, Comparator = Montelukast is the first listed.
NCT00045955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00045955 about?
NCT00045955 is a clinical study titled "Long-Term Safety Performance of Fexofenadine in Asthma". The purpose of this study is to assess the long-term safety performance of fexofenadine compared to montelukast in subjects with asthma
What is the current status of trial NCT00045955?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,200 participants. The study started on 2002-02. Estimated completion is 2003-11.
What interventions are being tested in trial NCT00045955?
The interventions under investigation include: Fexofenadine, Comparator = Montelukast (DRUG).
Who is sponsoring clinical trial NCT00045955?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.